News
The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...
9h
AllAfrica on MSNKenya to Roll Out Long-Acting Injectable HIV Prep Lenacapavir By Jan 2026Kenya is set to roll out the long-acting injectable HIV Pre-Exposure prophylaxis (PrEP) Lenacapavir by January 2026 following its approval by the World Health Organization.In a statement, Health ...
22h
AllAfrica on MSNSouth Africa Gets R520 Million to Buy the Twice-a-Year Anti-HIV Jab - But There's a SnagSA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
WHO releases new guidelines recommending injectable lenacapavir for HIV prevention: Geneva Wednesday, July 16, 2025, 10:00 Hrs [IST] The World Health Organization (WHO) released n ...
Explore more
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the ...
Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...
21h
Zacks.com on MSNMerck Starts Phase III Studies on Once-Monthly Pill for HIV PreventionMRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results